Quantitative NTCP pharmacophore and lack of association between DILI and NTCP Inhibition

European Journal of Pharmaceutical Sciences

Volumn 66, Issue , 2015, Pages 1-9

  Dong, Zhongqi ^a   Ekins, Sean ^b   Polli, James E ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b Collaborations in Chemistry ^*  (United States)

Author keywords

Drug induced liver injury (DILI); Hepatotoxicity; Quantitative pharmacophore; Sodium taurocholate cotransporting polypeptide (NTCP); Transporter

Indexed keywords

ACARBOSE; ACICLOVIR; AMPICILLIN; ATENOLOL; ATRACURIUM BESILATE; AZTREONAM; BENDROFLUMETHIAZIDE; BILE ACID; BORTEZOMIB; BOSENTAN; BUDESONIDE; CANDESARTAN; CAPTOPRIL; CARBAMAZEPINE; CEFACLOR; CEFTRIAXONE; CHLOROQUINE; CHLORPROMAZINE; CIMETIDINE; CIPROFLOXACIN; CYCLOSPORIN A; DANAZOL; DAUNORUBICIN; DILTIAZEM; DOXAZOSIN; ELETRIPTAN; ENALAPRIL; EPROSARTAN; SODIUM BILE ACID COTRANSPORTER; UNINDEXED DRUG; COTRANSPORTER; ORGANIC ANION TRANSPORTER; SODIUM-BILE ACID COTRANSPORTER;

ARTICLE; BILE ACID BLOOD LEVEL; CONTROLLED STUDY; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HYDROGEN BOND; HYDROPHOBICITY; LIVER TOXICITY; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; TOXIC HEPATITIS; ANTAGONISTS AND INHIBITORS; BIOLOGY; CHEMICAL AND DRUG INDUCED LIVER INJURY; DRUG DESIGN; DRUG EFFECTS; FACTUAL DATABASE; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; METABOLISM; PRECLINICAL STUDY; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION;

CHEMICAL AND DRUG INDUCED LIVER INJURY; COMPUTATIONAL BIOLOGY; DATABASES, FACTUAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; SYMPORTERS;

EID: 84949116661     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2014.09.005     Document Type: Article

References (32)

1. M.S. Anwer, and B. Stieger Sodium-dependent bile salt transporters of the SLC10A transporter family: more than solute transporters Pflugers Arch. 466 2013 77 89
2. B. Astorga, S. Ekins, M. Morales, and S.H. Wright Molecular determinants of ligand selectivity for the human multidrug and toxin extruder proteins MATE1 and MATE2-K J. Pharmacol. Exp. Ther. 341 2012 743 755
3. T. Bader, and B. Korba Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro Antiviral Res. 86 2010 241 245
4. H. Bahrami, N.E. Daryani, B. Haghpanah, A. Moayyeri, K.F. Moghadam, S. Mirmomen, and F. Kamangar Effects of indomethacin on viral replication markers in asymptomatic carriers of hepatitis B: a randomized, placebo-controlled trial Am. J. Gastroenterol. 100 2005 856 861
5. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA, Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism/Clinical Pharmacology Technical Working Group, FDA Center for Drug Evaluation and Research (CDER), 2003. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufactures of America (PhRMA) perspective. Drug Metab. Dispos. vol. 31, pp. 815-832.
6. C. Chang, K.S. Pang, P.W. Swaan, and S. Ekins Comparative pharmacophore modeling of organic anion transporting polypeptides: a meta-analysis of rat Oatp1a1 and human OATP1B1 J. Pharmacol. Exp. Ther. 314 2005 533 541
7. M. Chen, V. Vijay, Q. Shi, Z. Liu, H. Fang, and W. Tong FDA-approved drug labeling for the study of drug-induced liver injury Drug Discovery Today 16 2011 697 703
8. L. Diao, S. Ekins, and J.E. Polli Novel inhibitors of human organic cation/carnitine transporter (hOCTN2) via computational modeling and in vitro testing Pharm. Res. 26 2009 1890 1900
9. Z. Dong, S. Ekins, and J.E. Polli Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP) Mol. Pharm. 10 2013 1008 1019
10. S. Ekins, A.J. Williams, and J.J. Xu A predictive ligand-based Bayesian model for human drug-induced liver injury Drug Metab. Dispos. 38 2010 2302 2308
11. F. Gao, D.L. Johnson, S. Ekins, J. Janiszewski, K.G. Kelly, R.D. Meyer, and M. West Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50) J. Biomol. Screen. 7 2002 373 382
12. R. Greupink, S.B. Nabuurs, B. Zarzycka, V. Verweij, M. Monshouwer, M.T. Huisman, and F.G. Russel In silico identification of potential cholestasis-inducing agents via modeling of Na(+)-dependent taurocholate cotransporting polypeptide substrate specificity Toxicol. Sci. 129 2012 35 48
13. R.H. Ho, R.G. Tirona, B.F. Leake, H. Glaeser, W. Lee, C.J. Lemke, Y. Wang, and R.B. Kim Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics Gastroenterology 130 2006 1793 1806
14. D.W. Jun, B.I. Kim, Y.K. Cho, H.J. Kim, Y.O. Kwon, S.Y. Park, S.Y. Han, Y.H. Baek, Y.J. Jung, H.Y. Kim, W. Kim, J. Heo, H.Y. Woo, S.G. Hwang, K.S. Rim, J.Y. Choi, S.H. Bae, Y.S. Lee, Y.S. Lim, J.Y. Cheong, S.W. Cho, B.S. Lee, S.H. Kim, J.H. Sohn, T.Y. Kim, Y.H. Paik, J.K. Kim, and K.S. Lee Efficacy and safety of entecavir plus carnitine complex (GODEX®) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study Clin. Mol. Hepatol. 19 2013 165 172
15. S. Kapicioʇlu, M. Sari, K. Kaynar, A. Baki, and Y. Ozoran The effect of indomethacin on hepatitis B virus replication in chronic healthy carriers Scand. J. Gastroenterol. 35 2000 957 959
16. D. Keppler Cholestasis and the role of basolateral efflux pumps Z. Gastroenterol. 49 2011 1553 1557
17. V. Kolhatkar, and J.E. Polli Reliability of inhibition models to correctly identify type of inhibition Pharm. Res. 27 2010 2433 2445
18. V. Kolhatkar, and J.E. Polli Structural requirements of bile acid transporters: C-3 and C-7 modifications of steroidal hydroxyl groups Eur. J. Pharm. Sci. 46 2012 86 99
19. J. Lucifora, K. Esser, and U. Protzer Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes Antiviral Res. 97 2013 195 197
20. D. Schuster, C. Laggner, and T. Langer Why drugs fail - a study on side effects in new chemical entities Curr. Pharm. Des. 11 2005 3545 3559
21. C. Seeger, and W.S. Mason Sodium-dependent taurocholic cotransporting polypeptide: a candidate receptor for human hepatitis B virus Gut 62 2013 1093 1095
22. B. Stieger The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation Handb. Exp. Pharmacol. 201 2011 205 259
23. US Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research, 2009. Guidance for Industry: Drug-Induced Liver Injury: Premarketing Clinical Evaluation. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM174090.pdf.
24. F.M. Vaz, C.C. Paulusma, H. Huidekoper, M. de Ru, C. Lim, J. Koster, K. Ho-Mok, A.H. Bootsma, A.K. Groen, F.G. Schaap, R. Oude Elferink, H.R. Waterham, and R.J. Wanders Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: conjugated hypercholanemia without a clear clinical phenotype Hepatology 2014 (in press)
25. John G. Wagner Pharmacokinetics for the Pharmaceutical Scientist 1993 Technomic Publishing Co. Pennsylvania
26. K.K. Wolf, S. Vora, L.O. Webster, G.T. Generaux, J.W. Polli, and K.L. Brouwer Use of cassette dosing in sandwich-cultured rat and human hepatocytes to identify drugs that inhibit bile acid transport Toxicol. In Vitro 24 2010 297 309
27. H.Y. Xie, W.L. Xia, C.C. Zhang, L.M. Wu, H.F. Ji, Y. Cheng, and S.S. Zheng Evaluation of hepatitis B virus replication and proteomic analysis of HepG2.2.15 cell line after cyclosporine A treatment Acta Pharmacol. Sin. 28 2007 975 984
28. H. Yan, G. Zhong, G. Xu, W. He, Z. Jing, Z. Gao, Y. Huang, Y. Qi, B. Peng, H. Wang, L. Fu, M. Song, P. Chen, W. Gao, B. Ren, Y. Sun, T. Cai, X. Feng, J. Sui, and W. Li Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus Elife 1 2012 e00049
29. H. Yan, B. Peng, Y. Liu, G. Xu, W. He, B. Ren, Z. Jing, J. Sui, and W. Li Viral entry of Hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide J. Virol. 88 2014 3273 3284
30. S.B. Yanni, P.F. Augustijns, D.K. Benjamin Jr., K.L. Brouwer, D.R. Thakker, and P.P. Annaert In vitro investigation of the hepatobiliary disposition mechanisms of the antifungal agent micafungin in humans and rats Drug Metab. Dispos. 38 2010 1848 1856
31. i values against solute carrier transporters Eur. J. Pharm. Sci. 41 2010 43 52
32. X. Zheng, L. Diao, S. Ekins, and J.E. Polli Why we should be vigilant: drug cytotoxicity observed with in vitro transporter inhibition studies Biochem. Pharmacol. 80 2010 1087 1092